Published in Genome Medicine · View the paper (DOI)
A new study by Stanford Medicine scientists has identified a genetic variant that causes resistance to GLP-1 diabetes drugs in up to 10% of the population. The variant affects an enzyme called PAM, which handicaps the hormone's biological activity, leading to increased levels but reduced effectiveness.
Coverage from 2 institutions